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Objectives


Describe the pathophysiology of cystic fibrosis (CF)



Discuss updates in therapeutic management for patients with
acute and chronic CF



Formulate appropriate counseling points for a CF patient

What is Cystic Fibrosis?


Progressive, genetic disease that causes persistent lung
infections & limits the ability to breathe over time



Characterized by early colonization & infection of the airways



Produces buildup of mucus in the lungs, pancreas & other
organs

Epidemiology


More than 30,000 people in the United States living with CF



~1,000 new cases are diagnosed each year



More than half the population is over the age of 18



Frequently occurs in those of northern European ancestry



Lung disease is the major cause of morbidity and mortality in
patients with CF

Pathophysiology
Autosomal recessive genetic disorder
 Caused by mutations in the gene encoding for the CFTR
protein on chromosome 7
 Absence or dysfunction of the CFTR results in dehydrated,
thickened secretions that obstruct epithelium lined ducts
resulting in tissue damage
 Affects all exocrine glands


McNally P. Cystic Fibrosis. Netter’s Pediatrics.2011;41:246-249.

CFTR: cystic fibrosis
transmembrane conductance
regulator

Pathophysiology

Mucus
retention

Inflammation

Infection

What is cystic fibrosis? Stories. https://www.yourgenome.org/facts/what-is-cysticfibrosis. Published January 25, 2016. Accessed January 3, 2019.

CFTR Regulator Function
Largely expressed in the apical membranes of epithelial cells
that line the cylindrical structures of tissues that secrete fluids
rich in mucus & other proteins
 Belongs to family of transmembrane proteins called
adenosine triphosphate (ATP) binding cassette transporters
 1° role is to transport anions through the apical membrane of
epithelial cells creating an osmotic gradient for fluid secretion
 Function is to regulate:
 Chloride channel in apical membranes
 Epithelial sodium channels
 HCO3


Cantin AM, Hartl D, Konstan MW, Chmiel JF. Inflammation in cystic fibrosis lung disease: pathogenesis and therapy. J Cyst Fibros. 2015;14:419-430.

CFTR Mutations


~2,000 mutations have been identified in the CFTR gene since
its discovery in 1989
 ~242 mutations have been confirmed to cause CF
 Mutation F508del accounts for 70% of all mutations
• ~50% of patients worldwide are homozygous & 40%
are heterozygous



Mutations can be broadly classified into 6 categories

Cystic Fibrosis Foundation patient registry 2015: annual data report. Bethesda: Cystic Fibrosis Foundation; 2016.

CFTR Mutations

Elborn JS. Cystic fibrosis. Lancet. 2016;388(10059):2519–2531.

Diagnosis of Cystic Fibrosis

Prenatal
Screening

Newborn
Screening

Sweat
Test

Prenatal/Newborn Screening
Prenatal Screening
 The American College of Obstetricians and Gynecologists
recommends that pregnant women be offered screening
for CFTR mutations
 Prenatal diagnostic tests include chorionic villus
sampling & amniocentesis
 Newborn Screening
 Florida Statute 383.14(5)
 All newborn screening programs rely on elevations
of immunoreactive trypsinogen


Newborn Screening Program. Florida Department of Health. http://www.floridahealth.gov/programs-and-services/childrens-health/newborn-screening/nbs-disorder.html.

Sweat Test
“Woe is the child who tastes salty from a kiss on the brow, for he is cursed, and
soon must die."







Gold standard
Measurement of sweat Cl- by
quantitative pilocarpine iontophoresis
A sweat Cl- concentration > 60
mmol/L indicates a diagnosis of CF
A concentration of < 30 mmol/L
indicates that CF is unlikely

Farrell PM, White TB, Ren CL, Hempstead SE, Accurso F, Derichs N, Howenstine M, McColley SA, Rock M, Rosenfeld M, Sermet-Gaudelus I,
Southern KW, Marshall BC, Sosnay PR. Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation. J Pediatr. 2017
Feb;181S:S4-S15.e1.PMID: 28129811

Diagnosis: Testing: Sweat Test. Johns Hopkins Cystic
Fibrosis Center. https://www.hopkinscf.org/what-iscf/diagnosis/testing/sweat-test/. Accessed January 3,
2019.

Clinical Presentation


Manifestations of Cystic Fibrosis

Gastrointestinal system:
• Malnutrition
• Meconium ileus

Endocrine system:
• Cystic fibrosis-related diabetes

Reproductive system:
• Azoospermia in males
• Reduced fertility in females

Respiratory system

Shruti M. Paranjape, and Peter J. Mogayzel Jr Pediatrics in Review 2014;35:194-205

Respiratory system






Impaired mucociliary clearance resulting in thick sputum
Respiratory compromise characterized by copious
hyperviscous & adherent pulmonary secretions
Development of polyps in the sinus cavity
Chronic infections
Digital clubbing

Mayo Clinic Q and A: Diagnosing cystic fibrosis. Mayo Clinic. https://newsnetwork.mayoclinic.org/discussion/mayoclinic-q-and-a-diagnosing-cystic-fibrosis/. Accessed January 3, 2019.

Respiratory system


The dominant pathology in the lung is inflammation
generated by failure to clear microorganisms & generation of
a toxic pro-inflammatory local microenvironment



Airway secretions contain a complex bacterial flora
 Staphylococcus aureus, Haemophilus influenzae,
& Pseudomonas aeruginosa

Pharmacological Treatment


Goals of therapy:





Improve symptoms
Minimize loss of lung function
Minimize adverse drug reactions due to acute treatment



Effective airway clearance involves the use of a
bronchodilator, a mucolytic medication & chest percussion



Therapies directed towards the chronic infection in CF should
reduce inflammation

PHARMACOTHERAPY:
MUCOCILIARY CLEARANCE
Dornase Alfa (Pulmozyme®)
Hypertonic Saline

Mucociliary Transport

Ratjen F. Restoring airway surface liquid in cystic fibrosis. N Engl J Med. 2006;354:291-293.

Dornase Alfa (Pulmozyme®)


MOA: recombinant human deoxyribonuclease I (rhDNase)


Hydrolyzes the DNA in sputum of CF patients & reduces
sputum viscoelasticity



Dose: 2.5 mg single-use ampule inhaled once daily using a jet
nebulizer/compressor system



Ampules should be stored in their protective foil pouch under
refrigeration & protected from light



ADRs: Voice alteration, pharyngitis, rash, laryngitis, chest
pain, conjunctivitis, rhinitis, dyspepsia & dyspnea

Pulmozyme [package insert]. South San Francisco, CA: Genentech, Inc; 2014.

Mechanism of Action: MOA
Adverse Drug Reaction: ADR

Hypertonic Saline
Sterile, preservative-free sodium chloride inhaled solution
available in 3.5% & 7% strengths
 Indicated for ≥ 6 years old & those with an FEV1 ≥ 40%
 MOA: Mucolytic agent
 Restores moisture to pulmonary system
 ↑ hydration of airway surface liquid via osmotic flow





Dose: 4 mL/vial via inhalation BID
ADRs: Increased cough, sore throat & chest tightness

Elkins MR, Robinson M, Rose BR, Harbour C, Moriarty CP, Marks GB, Belousova EG, Xuan W, Bye PT. A controlled trial of long-term inhaled hypertonic saline in
patients with cystic fibrosis. N Engl J Med 2006;354:229–240.

Mechanism of Action: MOA
Forced Expiratory Volume: FEV

PHARMACOTHERAPY: RESTORATION
OF CFTR FUNCTION
Ivacaftor (Kalydeco®)
Lumacaftor + Ivacaftor (Orkambi®)
Tezacaftor + Ivacaftor (Symdeko®)

Ivacaftor (Kalydeco®)


MOA: Potentiator of the CFTR protein


Facilitates increased chloride transport



Baseline & follow-up ophthalmological exams are
recommended in pediatrics initiating Ivacaftor



Assess ALT & AST prior to initiation, every 3 months during
the 1st year of treatment & annually thereafter



ADRs: HA, oropharyngeal pain, URI, nasal congestion,
abdominal pain, nasopharyngitis, diarrhea, rash, nausea &
dizziness

Kalydeco (ivacaftor) [prescribing information]. Boston, MA: Vertex Pharmaceuticals Incorporated; August 2018.

Headache: HA
Upper Respiratory Infection: URI

Ivacaftor (Kalydeco®)
Dosing Regimen







Age ≥ 6 years

150 mg tablet PO every 12 hours

Age 1-5 years and weighing 7 kg to < 14 kg

One 50 mg packet PO every 12 hours

Age 1-5 years and weighing ≥ 14 kg

One 75 mg packet PO every 12 hours

Available as oral tablets for patients ≥ 6 years old & oral granules for
patients 1-5 years of age
Once mixed, oral granules should be consumed within the hour
Should be taken with fat containing foods
Co-administration with:

Strong CYP3A inducers: not recommended

Strong CYP3A inhibitors: dose should be reduced to one tablet or one
packet of oral granules twice a week

Kalydeco (ivacaftor) [prescribing information]. Boston, MA: Vertex Pharmaceuticals Incorporated; August 2018.

Gene mutations responsive to Ivacaftor (Kalydeco®)
E56K

G178R

S549R

S977F

F1074L

2789+5GA

P67L

E193K

G551D

F1052V

D1152H

3272-26AG

R74W

L206W

G551S

K10607

G1244E

3849+10kbCT

D110E

R347H

D579G

A1067T

S125IN

D110H

R352Q

711+3AG

G1069R

D1270N

R117C

A455E

E831X

R1070Q

G1349D

R117H

S549N

S945L

R1070W

S1255P

Kalydeco (ivacaftor) [prescribing information]. Boston, MA: Vertex Pharmaceuticals Incorporated; August 2018.

Lumacaftor + Ivacaftor (Orkambi®)



Indicated for pts > 2 years who are homozygous for the
F508del mutation in the CFTR gene
MOA:



Lumacaftor improves the conformational stability of F508del-CFTR
Ivacaftor is a CFTR potentiator that facilitates increased Cl- transport

Orkambi [prescribing information]. Boston, MA: Vertex Pharmaceuticals Incorporated; September 2016.

Lumacaftor + Ivacaftor (Orkambi®)
Dosing Regimen
Age
2-5 years of age and weighing > 14 kg

One lumacaftor 100 mg/ ivacaftor 125 mg packet of granules every 12 hours

2-5 years of age and weighing ≥ 14 kg

One lumacaftor 150 mg/ ivacaftor 188 mg packet of granules every 12 hours

6-11 years of age

Two lumacaftor 100 mg/ivacaftor 125 mg tablets every 12 hours

12 years and older

Two lumacaftor 200 mg/ivacaftor 125 mg tablets every 12 hours



Should be taken with fat containing foods



ADRs: dyspnea, nasopharyngitis, nausea, diarrhea, URI,
fatigue, ↑ blood CPK, rash, flatulence, rhinorrhea & influenza

Orkambi [prescribing information]. Boston, MA: Vertex Pharmaceuticals Incorporated; September 2016.

Creatinine Phosphokinase: CPK

Tezacaftor + Ivacaftor (Symdeko®)


Indicated for pts > 12 years of age who are homozygous for the
F508del mutation or who have > 1 mutation in the CFTR gene
that is responsive to tezacaftor/ivacaftor
Gene mutations responsive to Tezacaftor + Ivacaftor (Symdeko®)

F508del

R117C

D579G

K1060T

2789+5GA

E56K

E193K

711+3AG

A1067T

3272-26AG

P67L

L206W

E831X

R1070W

3849+10kbCT

R74W

R347H

S945L

F1074L

D110E

R352Q

S977F

D1152H

D110H

A455E

F1052V

D1270N

Symdeko [prescribing information]. Boston, MA: Vertex Pharmaceuticals Incorporated; February 2018

Tezacaftor + Ivacaftor (Symdeko®)
MOA:
 Tezacaftor: Facilitates cellular processing & trafficking of CFTR to
↑ amount of mature CFTR protein delivered to the cell surface
 Ivacaftor: CFTR potentiator that facilitates increased Cl- transport

Symdeko [prescribing information]. Boston, MA: Vertex Pharmaceuticals Incorporated; February 2018

Tezacaftor + Ivacaftor (Symdeko®)


Packaged as tezacaftor 100 mg/ivacaftor 150 mg fixed dose
combination tab & ivacaftor 150 mg tab



Dose: One tab (tezacaftor 100 mg + ivacaftor 150 mg) in AM
and one tab (ivacaftor 150 mg) in PM



Should be taken with fat containing foods



Requires dose reduction in pts with hepatic impairment &
those taking concomitant CYP inducers or inhibitors



ADRs: HA, nausea, sinus congestion & dizziness

Symdeko [prescribing information]. Boston, MA: Vertex Pharmaceuticals Incorporated; February 2018

Mechanism of Action: MOA
Headache: HA

PHARMACOTHERAPY: ANTIINFECTIVES
Amikacin Liposome Inhalation Suspension (Arikayce®)
Azithromycin (Zithromax®)
Aztreonam (Cayston®)
Tobramycin (TOBI Podhaler®, Bethkis®)

Cystic Fibrosis Foundation Patient Registry. 2017 Annual Data Report. Bethesda, Maryland. Cystic Fibrosis Foundation; 2018.

Pseudomonas aeruginosa


Gram negative rod widely distributed in nature & commonly
present in moist environments



Most frequently encountered lung pathogen in CF



~80% of patients are chronically colonized by Pseudomonas
aeruginosa by the age of 20



Colonization & infection with Pseudomonas aeruginosa remains
the most important contributor to CF morbidity & mortality

Amikacin Liposome Inhalation
Suspension (Arikayce®)


Approved in Sep. 2018 under the Accelerated Approval Pathway



Criteria for indication:






Adults with Mycobacterium avium complex (MAC)
Limited/no alternative treatment options
Failed to achieve negative sputum cultures after a minimum of 6
consecutive months of a multidrug background regimen therapy

MOA: Disruption & inhibition of protein synthesis in the target
bacteria by binding to the 30S ribosomal subunit

Arikayce [package insert]. Bridgewater, NJ: Insmed Incorporated; 2018.

Amikacin Liposome Inhalation
Suspension (Arikayce®)


Dose: Once daily oral inhalation of the contents of one 590
mg/8.4 mL Arikayce® vial
 To be used only with the Lamira™ Nebulizer System



ADRs: Dysphonia, cough, bronchospasm, hemoptysis,
musculoskeletal pain, fatigue/asthenia & exacerbation of
underlying pulmonary disease

Arikayce [package insert]. Bridgewater, NJ: Insmed Incorporated; 2018.

Azithromycin (Zithromax®)


MOA: Inhibits RNA-dependent protein synthesis at the chain
elongation step by binding to the 50S ribosomal subunit





Dose:





Contains anti-inflammatory properties that may benefit CF patients
Exact mechanism in CF is still unknown

< 40 kg: 250 mg three times weekly
≥ 40 kg: 500 mg three times weekly

ADRs: Nausea, diarrhea, & wheezing

Azithromycin (Zithromax®)


Treatment of pts with CF chronically infected with P.
aeruginosa with azithromycin led to ↓ morbidity & mortality





Pulmonary function & nutritional status improved
Pulmonary exacerbation rates decreased

Emergence of macrolide-resistant nontuberculous
mycobacteria is of concern when considering chronic
azithromycin therapy


MDs considering azithromycin therapy should assess patients
with CF for nontuberculous mycobacteria before & every 6
months after initiating azithromycin

Saiman L, Marshall BC, Mayer-Hamblett N, et al. Azithromycin in patients with cystic fibrosis chronically infected with pseudomonas aeruginosa: a randomized controlled trial. JAMA. 2003;290(13):1749-1756.

Aztreonam (Cayston®)




An aerosolized formulation of the monobactam antibiotic
aztreonam & lysine
Indicated to improve respiratory symptoms in CF pts ≥ 7 years
old with Pseudomonas aeruginosa
MOA: Binds to penicillin-binding proteins of susceptible
bacteria, which leads to inhibition of bacterial cell wall
synthesis & death of the cell

McCoy K.S., Quittner A.L., Oermann C.M., Gibson R.L., Retsch-Bogart G.Z., and Montgomery A.B.: Inhaled aztreonam lysine for
chronic airway Pseudomonas aeruginosa in Cystic Fibrosis. Am J Respir Crit Care Med 2008; 178: pp. 921-928
Cayston[package insert]. Foster City, CA: Gilead Sciences Incorporated; 2014.

Aztreonam (Cayston®)


Dose: Inhale one single use vial (75 mg aztreonam)
reconstituted with 1 mL of sterile diluent TID for a 28 day
course, followed by 28 days off drug




To be used only with the Altera® Nebulizer System

ADRs: cough, nasal congestion, wheezing, pharyngolaryngeal
pain, pyrexia, chest discomfort, abdominal pain & vomiting

Cayston[package insert]. Foster City, CA: Gilead Sciences Incorporated; 2014.

Tobramycin (TOBI Podhaler®)
MOA: Aminoglycoside antimicrobial that acts primarily by
disrupting protein synthesis in the bacterial cell which
eventually leads to cell death
 Dose: Inhalation of the contents of four TOBI Podhaler®
capsules twice daily for 28 days, followed by 28 days off drug







One capsule contains 28 mg tobramycin
Capsules should be used with the Podhaler device only

ADRs: cough, dyspnea, pyrexia, oropharyngeal pain,
dysphonia, hemoptysis, & HA

TOBI [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2015

Tobramycin (Bethkis®)
MOA: Aminoglycoside antimicrobial that acts primarily by
disrupting protein synthesis in the bacterial cell which
eventually leads to cell death
 Dose: One ampule BID by oral inhalation in repeated cycles of
28 days on drug, followed by 28 days off drug









One 4 mL ampule contains 300 mg tobramycin
Administered using a hand-held PARI LC PLUS Reusable Nebulizer with
a PARI Vios Air compressor

ADRs: ↓ FEV, rales, ↑ red blood cell sedimentation rate, &
dysphonia
Light sensitive
Store in refrigerator

Bethkis [package insert]. Cary, NC: Chiesi, Inc.; 2017.

Forced Expiratory Volume: FEV

THE ROLE OF A PHARMACIST

The Role of a Pharmacist
Identify potential drug interactions
 Kalydeco , Symdeko, and Orkambi
• Substrates of CYP3A4
 Patient Counseling
 Encourage adherence to medication regimen
 Verify appropriate inhaler/nebulizer technique
 Kalydeco, Symdeko, and Orkambi should be taken with high fat
meals
 Ensure correct antibiotic selection in the setting of an acute
exacerbation
 Broad spectrum coverage
 Two antipseudomonal agents


Acute Exacerbations


Diagnosis of an acute exacerbation is based on changes from
an individual pt’s recent baseline health status



Most exacerbations are not associated with the appearance
of bacterial species or strains that are new to the pt



Treatment:






Continuation of chronic treatment regimen
Glucocorticoids
Respiratory support
Systemic antibiotics

Pharmacokinetics in CF Population





Large volumes of distribution
Enhanced metabolic clearance
Increased risk for antimicrobial resistance
Difficulty with lung tissue penetration

Great difficulty in attaining & maintaining
therapeutic drug concentrations!

Chronic CF Therapies:
Recommended Order
Bronchodilator
Hypertonic Saline
Dornase alfa
Airway clearance

Aerosolized antibiotics

Mogayzel PJ Jr, et al. Am J Respir Crit Care Med. 2013;187(7):680-689.

WHAT’S NEXT?
The Future of CF

New Therapies


CF care has largely focused on the downstream effects of
CFTR dysfunction



New therapies aim to treat the underlying abnormality



CF has among the highest number of gene-therapy trials



CFTR pharmacotherapy:





CFTR gene mutations have different functional consequences



Must target the distinct classes of mutation

Treating the early & root causes of CF will improve outcomes
& reduce the burdens of treatment

New Therapies


Introduction of CFTR modulators has revolutionized CF care



Drug screening campaigns have identified agents capable of
suppressing CFTR nonsense alleles, augmenting potentiator
activity & further promoting F508del correction



Advancement of new drugs that address specific CFTR defects
has been bolstered by clinical studies of F508del rescue in
combination with ivacaftor

Drug Development Pipeline
Phase 1

Phase 2

Phase 3

Eluforsen (QR-010)

QBW251

VX-445 + tezacaftor + ivacaftor

MRT5005

FDL169

VX-659 + tezacaftor + ivacaftor

AZD5634

GLPG2222

Inhaled Mannitol (Bronchitol®)

ALX-009

PTI-428

Inhaled Levofloxacin (Quinsair®)

SNSP113

PTI-801

Vancomycin Inhalation Powder
(AeroVanc®)

SPI-1005

VX-561

POL6014

OligoG
SPX-101
Inhaled Nitric Oxide
Intravenous Gallium
Acebilustat (CTX-4430)
Lenabasum (JBT-101)
LAU-7b

Summary


CF is a disease state resulting from a dysfunction in the CFTR



Multiple organ systems are affected in CF individuals



Mortality is most commonly due to chronic organ damage or
resistant pulmonary infections



Breakthrough in CF treatment focuses on treating the basic
defect of the disease: CFTR dysfunction

Test Your Knowledge
True or False?


The most common cause of pneumonia in patients with cystic
fibrosis is burkholderia cepacia. FALSE



Inhaled antibiotics, such as Aztreonam (Cayston®) and
Tobramycin (TOBI®), should be administered last in a patient’s
inhaled medication regimen after bronchodilators and other
inhaled therapies. TRUE



The most common CFTR gene mutation is delta F508. TRUE
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